Anzeige
Mehr »
Dienstag, 07.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QP3D | ISIN: CA64082X2032 | Ticker-Symbol: 9UA
Tradegate
06.10.25 | 15:33
2,540 Euro
-3,05 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NERVGEN PHARMA CORP Chart 1 Jahr
5-Tage-Chart
NERVGEN PHARMA CORP 5-Tage-Chart
RealtimeGeldBriefZeit
2,5602,66006.10.
2,5602,66006.10.

Aktuelle News zur NERVGEN PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.NervGen Pharma price target chopped at Research Capital6
26.08.NervGen Pharma Corp.: NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders348Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal...
► Artikel lesen
21.08.Nervgen Pharma Corp: Nervgen's NVG-291-R studies suggest hearing recovery1
NERVGEN PHARMA Aktie jetzt für 0€ handeln
21.08.NervGen Pharma Corp.: NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury368Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced...
► Artikel lesen
23.07.NervGen Pharma is a buy, Research Capital says15
19.07.Nervgen Pharma Corp: Nervgen Pharma prospectus offering of 385,200 shares3
17.07.Nervgen Pharma Corp: Nervgen president, CEO, director Kelly resigns1
17.07.NervGen Pharma announces CEO transition5
17.07.NervGen Pharma Corp.: NervGen Announces Leadership Transition to Support Strategic Growth and Expansion387Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies...
► Artikel lesen
08.07.Nervgen Pharma Corp: Nervgen sells 385,200 shares under ATM program in Q25
07.07.NervGen Pharma Corp.: NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update521Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing...
► Artikel lesen
04.07.Nervgen Pharma Corp: Nervgen Pharma director Ives resigns3
03.07.NervGen Pharma Corp.: NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth530Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI StudyVancouver, British Columbia--(Newsfile Corp....
► Artikel lesen
01.07.NervGen Pharma Corp.: NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones512Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics...
► Artikel lesen
18.06.Nervgen Pharma Corp: Nervgen appoints Kaye as chief medical adviser2
18.06.NervGen Pharma Corp.: NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role300Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics...
► Artikel lesen
18.06.Paradigm Capital doubles its price target on NervGen Pharma3
02.06.Nervgen Pharma Corp: Nervgen finds NVG-291 meets co-primary end point14
02.06.NervGen Pharma stock tumbles following clinical trial results5
02.06.Nervgen Pharma Corp: Nervgen Pharma resumes at 7:15 a.m. PT4
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1